Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Net Income towards Common Stockholders (2023 - 2025)

Historic Net Income towards Common Stockholders for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.9 million.

  • BioLineRx's Net Income towards Common Stockholders rose 4941.52% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year increase of 5725.76%. This contributed to the annual value of -$19.3 million for FY2024, which is 5942.77% up from last year.
  • BioLineRx's Net Income towards Common Stockholders amounted to -$1.9 million in Q3 2025, which was up 4941.52% from -$2.0 million recorded in Q2 2025.
  • BioLineRx's 5-year Net Income towards Common Stockholders high stood at -$1.9 million for Q3 2025, and its period low was -$19.5 million during Q4 2023.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$5.4 million (2024), whereas its average is -$6.7 million.
  • The largest annual percentage gain for BioLineRx's Net Income towards Common Stockholders in the last 5 years was 6734.38% (2024), contrasted with its biggest fall of 3149.2% (2024).
  • Over the past 3 years, BioLineRx's Net Income towards Common Stockholders (Quarter) stood at -$19.5 million in 2023, then skyrocketed by 59.28% to -$7.9 million in 2024, then skyrocketed by 76.03% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$2.0 million for Q2 2025, and -$2.0 million during Q1 2025.